Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.

Regency Centers Corporation

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a late-stage study on n...

Regeneron Targets Cat Allergy Eye Relief With New Phase 3 Antibody Trial

In a report released on August 6, Yang Huang from J.P. Morgan maintained a Buy rating on RemeGen Co. Ltd. Class H, with a price target of HK$129.00...

J.P. Morgan Reaffirms Their Buy Rating on RemeGen Co. Ltd. Class H (9995)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The phase 1/2 study titled “REGN15505 Alone or in Combinatio...

Regeneron Targets Next‑Gen Cancer Immunotherapy With New Phase 1/2 Trial

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Regeneron, with a price target of $917.00. According to TipRanks,...

Barclays Keeps Their Buy Rating on Regeneron (REGN)

An update from Eregli Demir Ve Celik Fabrikalari T.A.S. ( ($TR:EREGL) ) is now available. Trading in EREGL.E shares was temporarily halted when an ...

Trading in EREGL.E Halted by Circuit Breaker, Set to Resume After Call Auction

CMBC International analyst maintained a Buy rating on RemeGen Co. Ltd. Class H yesterday and set a price target of HK$125.75. The company’s shares ...

RemeGen Co. Ltd. Class H (9995) Gets a Buy from CMBC International

Truist Financial analyst Gregory Renza maintained a Buy rating on Regeneron today and set a price target of $772.00. Renza covers the Healthcare se...

Truist Financial Remains a Buy on Regeneron (REGN)

There’s a lot to be optimistic about in the Real Estate sector as 2 analysts just weighed in on Newmark Group (NMRK) and Regency Centers (REG) with...

Analysts Are Bullish on These Real Estate Stocks: Newmark Group (NMRK), Regency Centers (REG)

The latest announcement is out from Regency Centers ( ($REG) ). Regency Centers reported solid financial and operating results for the second quart...

Regency Centers Raises 2026 Guidance After Strong Quarter

Regency Centers ( ($REG) ) has provided an announcement. Regency Centers reported solid second-quarter 2026 results on July 29, 2026, with net inco...

Regency Centers Delivers Strong Second-Quarter 2026 Performance

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a new Phase 4 study in ...

Regeneron Targets Safer Outpatient Myeloma Care With New Linvoseltamab Study

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing a federal securities lawsuit alleging that investors were not fully informed about risks t...

Regeneron Pharmaceuticals Lawsuit Alleges Investors Were Misled Before REGN Stock Drops 

Creactives Group S.p.A. ( ($IT:CREG) ) has provided an update. Creactives Group has approved amendments to its non-convertible bond, changing its n...

Creactives Group Extends Bond Maturity and Lowers Coupon Rate

Nomura analyst maintained a Hold rating on RemeGen Co. Ltd. Class H on July 24 and set a price target of HK$89.44. The company’s shares closed yest...

Nomura Keeps Their Hold Rating on RemeGen Co. Ltd. Class H (9995)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN), Celldex (CLDX) and Nurix Therapeut...

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Celldex (CLDX) and Nurix Therapeutics (NRIX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Valneva (VALN), Regeneron (REGN) and Telix Pharmaceu...

Analysts Are Bullish on These Healthcare Stocks: Valneva (VALN), Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals has finished a mid stage study tes...

Regeneron’s POTS Study Wraps Up: What REGN7544 Could Mean for REGN Investors

Smart Powerr Corp ( ($CREG) ) has issued an announcement. On July 17, 2026, Smart Powerr Corp. received a delisting notice from Nasdaq stating that...

Smart Powerr Corp Faces Nasdaq Delisting, OTCQB Move

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study, officially titled “PRospEctiVe c...

Real-World Asthma Data on Dupixent: What Regeneron and Sanofi Investors Should Know

RBC Capital analyst Craig Wong-Pan maintained a Buy rating on Regis Healthcare Ltd. on July 16 and set a price target of A$7.50. The company’s shar...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REG	$76.71	-0.20%	645.17K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REG	$76.71	-0.2%	645.17K
3
4
5
6

REG

Get Regency Centers Corporation Data in Excel

Get Regency Centers Corporation Data in Excel